Clinical Trials Logo

Diabetic Foot clinical trials

View clinical trials related to Diabetic Foot.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06464250 Completed - Diabetic Foot Ulcer Clinical Trials

The Effect of Bundle Approach on Foot Care Behaviors and Diabetic Wound Healing in Patients

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This study was planned to standardize foot care behaviors with a patient-participated care package approach, to ensure healing of existing wounds, and to evaluate the effect on foot care behaviors to prevent the development of new diabetic foot ulcers. The sample of the study consisted of a total of 97 patients, 49 patients in the care package group and 48 patients in the control group. Hypotheses of the Study H1. The foot care behaviors of patients who receive a patient-participatory care package approach to diabetic foot ulcer prevention will be higher than those of patients who do not receive a care package. H2. Patient-involved care package approach prevents the development of new diabetic foot ulcers. H3. Patient-involved care package approach provides healing of existing diabetic ulcers.

NCT ID: NCT06450015 Completed - Diabetic Foot Clinical Trials

Comparison of Vacuum Assisted Closure and Saline Dressing in Patients With Diabetic Foot Ulcers

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Conventionally diabetic foot is treated with moist wound dressing and antibiotics but recent studies show that VAC dressing gives better results as compared to conventional saline dressing in treating Diabetic Foot Ulcers. This may decrease amputations rate, work load on hospitals, hospital stay, repeated hospital admissions, unemployment and can improve patient's quality of life. Objective of the study was to compare the effectiveness of Vacuum Assisted Closure therapy with saline dressing in management of diabetic foot ulcers in terms of granulation tissue formation and wound healing.

NCT ID: NCT06442865 Completed - Diabetic Foot Clinical Trials

AMNIODERM+ Medical Device Clinical Study

AMNIODERM+
Start date: November 16, 2022
Phase:
Study type: Observational

This is retrospectively-prospective clinical trial with medical device AMNIODERM+ intended for the non-healing wounds. Retrospective data will contain information about the subject's history and wound treatment by SoC. Prospective data will contain information about wound treatment by AMNIODERM+®.

NCT ID: NCT06434922 Completed - Quality of Life Clinical Trials

Prevention and Early Detection of Ulcer Recurrence in Patients With Type II Diabetes Mellitus

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to to evaluate the effectiveness of prevention strategies of recurrence in DFU's. It will also to detect the risk level of recurrence. The main question it aims to answer are: - Does intervention of prevention strategies effective to prevent the recurrence of DFU's? - How the risk level of the recurrence on DFU's patients? - How the impact of quality of life on DFU's patients? Researchers will compare intervention groups (receiving education covered various aspects, including they received guidance on foot examination, foot care, dietary habits, physical exercise, and stress management), and control groups (received standards follow-up care provided by healthcare providers, including pamphlets outlining care for DM patients based on the five pillars, including DM management, medication adherence, dietary practices, physical exercise routines, and foot care). Participants will: - For intervention group will be educated every month - Data for both intervention and control groups were collected monthly until three months.

NCT ID: NCT06373809 Completed - Diabetic Foot Ulcer Clinical Trials

Placenta Derived Stem Cells for Treating of Chronic Ulcers and Neuropathy

PDSC
Start date: October 8, 2021
Phase: Early Phase 1
Study type: Interventional

This is an initial dose escalation safety and exploratory efficacy study to treat two groups of subjects with critically sized diabetic wounds and diabetic neuropathy using placental-derived stem cells (PDSC) transplanted by injection into soft tissues of the lower limb. Its primary objective is safety assessment and its secondary objective is determining optimum PDSC safe dose. Group 1 will receive implantation of cells in the ulcer, in the ulcer bed, and along the distal arterial vessels that supply blood to the foot. Group 2 will follow the same protocol for the foot but will have an additional dose of cells implanted in the anterior and posterior compartments of the same leg to determine the impact on peripheral neuropathy. Dose escalation and safety will be documented. Exploratory measures of efficacy include: ulcer healing, hemodynamic and anatomical effects on the arteries of the foot, and changes in the sensory perceptions of the foot.

NCT ID: NCT06288555 Completed - Diabetic Foot Clinical Trials

Validation of Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening in Primary Care

Start date: December 21, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to assess the accuracy of screening for diabetic peripheral neuropathy by comparing the Ipswich touch test with the 10-g monofilament test in patients diagnosed with type 2 diabetes. The main question it aims to answer is: How does the accuracy of the Ipswich Touch Test for identifying peripheral neuropathy compare to the traditional 10-g monofilament test? Participants underwent both the Ipswich touch test and the 10-g monofilament test.

NCT ID: NCT06280053 Completed - Burn Wound Clinical Trials

HealiAid in the Treatment of Different Wounds

Start date: March 2, 2016
Phase: N/A
Study type: Interventional

The goal of this open-label, post-market clinical follow-up study is to demonstrate the safety and effectiveness of HealiAid Collagen Wound Dressing in patients classified into different types of wounds: venous ulcers, bedsores, diabetic foot wounds and burn wounds. The main questions it aims to answer are: 1. The wound healing which was defined as the percentage of area change. 2. The duration of wound healing. 3. The granulation tissue growth of the wound. 4. The wound exudate. 5. Safety Indicators of which incidences after treatment. HealiAid will be applied to eligible subjects who will later be followed up for 12 weeks.

NCT ID: NCT06250049 Completed - Diabetes Clinical Trials

Improvement of Diabetic Foot Care in Salamanca Through the Implementation of Standardized Protocols.

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Introduction: Diabetic foot (DF) is among the most prevalent complications affecting individuals with diabetes. In Salamanca, 25,631 individuals are enrolled in the Diabetes Care Service, with only 3.06% undergoing a foot examination. Objective: To evaluate the effectiveness of implementing a standardized foot care protocol for individuals with diabetes, accompanied by a sensitization and training strategy for nursing professionals. Methodology: Quasi-experimental pre- and post-study with a control group conducted in the Health Centers of Salamanca. Population: Patients included in the Diabetes Care Service (306) (12,458 men and 11,348 women). Measurements: In professionals: number of professionals involved and satisfaction level. In diabetic individuals: Sociodemographic, anthropometric, lifestyle, and clinical variables related to disease control will be measured, along with variables related to protocol implementation (percentage of diabetics who have undergone foot examination, Ankle-Brachial Index (ABI), risk stratification and foot monitoring, percentage of individuals with DF, percentage of individuals with healed DF ulcers, and percentage of individuals who have undergone amputation). Improvement in quality of life will be measured using the COOP-WONCA questionnaire. Expected outcomes: It is anticipated that this study will provide evidence regarding the relationship between protocol implementation and an increase in the detection and care of at-risk feet and DF, as well as an improvement in the quality of life of individuals with diabetes.

NCT ID: NCT06160817 Completed - Diabetic Foot Ulcer Clinical Trials

Ulcer Location and Debridement Frequency: Weekly vs. Biweekly Sharp Debridement in Diabetic Foot Ulcers

Start date: January 11, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to determine the optimal frequency for sharp debridement in promoting the healing of diabetic foot ulcers (DFUs). The main questions it aims to answer are: 1. What is the comparative effect of weekly sharp debridement versus biweekly sharp debridement in combination with conventional treatment on granulation tissue and healing time in patients with DFUs? 2. What is the optimal modality or frequency of debridement based on the location of the DFU? Participants (ulcerated diabetic patients) will: - Undergo sharp debridement on a weekly basis (Group A). - Undergo sharp debridement on a biweekly basis (Group B). Researchers will compare Group A (weekly sharp debridement) with Group B (biweekly sharp debridement ) to see if the frequency of sharp debridement has a significant effect on granulation tissue and healing time in diabetic foot ulcers. In each group, there will be patients with ulcers in different locations (toes, metatarsal heads, and midfoot/hindfoot) to assess the effect of debridement based on the lesion location

NCT ID: NCT06084052 Completed - Diabetic Foot Clinical Trials

Path Active; Safety and Tolerability Study

PASTS
Start date: August 1, 2023
Phase: N/A
Study type: Interventional

Path Active™ comprises a pair of monitoring insoles which measure parameters associated with foot ulceration in diabetes: temperature and pressure. The insoles are linked via an app to the wearer's mobile phone and also to a clinical dashboard so that both wearer and clinician are alerted to early signs of skin damage on the foot so that immediate preventive action can be taken. The study will assess safety and tolerability of Path Active™ in 10 users, who have been assessed as having a 'high risk' of foot ulceration, over a period of 7 days.